← Back to Clinical Trials
Recruiting NCT04787848

Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

Trial Parameters

Condition Chronic Widespread Pain
Sponsor Florida International University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 19 Years
Max Age 65 Years
Start Date 2021-11-15
Completion 2026-07-30
Interventions
Relistor Injectable Product

Brief Summary

To determine if decreased production or release of endogenous opioid peptides by peripheral immune cells contributes to hypersensitivity in people with HIV

Eligibility Criteria

Inclusion Criteria: * Confirmed HIV diagnosis and currently a patient in the UAB 1917 HIV Clinic * Age 19 - 65; the lower end of this age range was chosen to capture young adults with HIV infection, and participants over 65 years are increasingly likely to meet one or more exclusion criteria * All people living with HIV must be currently receiving stable antiretroviral therapy (ART) for inclusion in this study * Non-HIV participants must be confirmed as HIV negative. HIV-negative participants with chronic widespread pain must self-report bodily pain more than once per week for at least three consecutive months and HIV-negative participants without chronic pain must self-report no pain, or pain less frequently than once per week for at least three consecutive months Exclusion Criteria: * Anemia * Current or past history of blood disorders which may increase hemolysis * Active microbial infections which may alter the quantity or quality of blood inflammatory cells such as monocytes and n

Related Trials